<DOC>
	<DOCNO>NCT02111135</DOCNO>
	<brief_summary>Phase II , observer-blind , randomize study safety , reactogenicity , immunogenicity impact intestinal shed single dose monovalent high-dose inactivate poliovirus type 2 vaccine ( m-IPV2 HD ) single dose standard trivalent inactivate poliovirus vaccine ( t-IPV ) give concomitantly third dose bivalent oral poliovirus vaccine ( b-OPV ) infant early life</brief_summary>
	<brief_title>Safety Study Single Dose Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine ( m-IPV2 HD ) Infants Early Life</brief_title>
	<detailed_description />
	<criteria>1 . Age : 6 week ( 7 +14 day ) . 2 . Healthy without obvious medical condition preclude subject study establish medical history physical examination . 3 . Written inform consent obtain 1 2 parent legal guardian per Panama regulation . 1 . Previous vaccination poliovirus . 2 . Low birth weight ( BW &lt; 2,500 gm ) . 3 . Any confirmed suspected immunosuppressive immunodeficient condition include human immunodeficiency virus ( HIV ) infection . 4 . Family history congenital hereditary immunodeficiency . 5 . Major congenital defect serious uncontrolled chronic illness ( neurologic , pulmonary , gastrointestinal , hepatic , renal , endocrine ) . 6 . Known allergy component study vaccine . 7 . Uncontrolled coagulopathy blood disorder contraindicate intramuscular injection . 8 . Administration immunoglobulins and/or blood product since birth plan administration study period . 9 . Acute severe febrile illness day vaccination deem Investigator contraindication vaccination ( child include late time within age window in/exclusion criterion met. ) . 10 . Member subject 's household ( live house apartment unit ) receive OPV last 3 month . 11 . Subject , opinion Investigator , unlikely comply protocol inappropriate include study safety benefitrisk ratio subject .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>6 Weeks</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>